Innovo Therapeutics
- Biotech or pharma, therapeutic R&D
Objective: Seeking corporate partnerships/out-licensing and series-A funding
Our proprietary molecular glue platform has generated three first-in-class degraders: INNO-740, set to enter Phase 1 trials in 2025 for hematologic malignancies; INNO-1443 and INNO-1645, targeting two distinct transcription factors, for gastric and RCC.
Address
San DiegoCalifornia
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}